← Leaderboards
Selvarangan Ponnazhagan
University Of Alabama At Birmingham
$11,274,357
Attributed
$11,274,357
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,839,479 · 11
By mechanism
R01$11,095,313 · 8
P30$565,122 · 2
P20$179,044 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Barbara A. Gower$29,302,489
- Jay M McDonald$5,565,578
- Timothy R Nagy$8,655,738
- Joel N Glasgow$196,342
- Alfred A Bartolucci$975,195
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsIn VivoMouse ModelTumorPre-ClinicalBaseOsteoblastsBoneNeoplastic CellHomingMesenchymal Stem CellsPathologyMolecularBone RemodelingSignal TransductionProductionOsteoclastsTherapeutic EffectAdeno-Associated Viral VectorLeadRecombinant Adeno-Associated Virus (Raav)Bone MarrowMediatingMorbidity - Disease Rate
Grant awards (43)
Mechanisms and therapeutic targeting of osteoimmune functions of RANKL in breast cancer$417,719
R01 · FY2025 · CA · contact PI
Mechanisms and therapeutic targeting of osteoimmune functions of RANKL in breast cancer$396,834
R01 · FY2024 · CA · contact PI
Mechanisms and therapeutic targeting of osteoimmune functions of RANKL in breast cancer$446,708
R01 · FY2023 · CA · contact PI
Targeted therapy for breast cancer with osteolytic bone damage$326,174
R01 · FY2019 · CA · contact PI
Targeted therapy for breast cancer with osteolytic bone damage$336,263
R01 · FY2018 · CA · contact PI
Targeted therapy for breast cancer with osteolytic bone damage$336,263
R01 · FY2017 · CA · contact PI
Pilot Project #2$44,761
P20 · FY2017 · CA · contact PI
Targeted therapy for breast cancer with osteolytic bone damage$336,263
R01 · FY2016 · CA · contact PI
Targeted Stem Cell Therapy Coupling Angiogenesis and Osteogenesis for Bone Defect$329,625
R01 · FY2016 · AR · contact PI
Pilot Project #2$44,761
P20 · FY2016 · CA · contact PI
Targeted therapy for breast cancer with osteolytic bone damage$321,211
R01 · FY2015 · CA · contact PI
Pilot Project #2$44,761
P20 · FY2015 · CA · contact PI
Targeted Stem Cell Therapy Coupling Angiogenesis and Osteogenesis for Bone Defect$323,032
R01 · FY2014 · AR · contact PI
Pilot Project #2$44,761
P20 · FY2014 · CA · contact PI
Targeted Stem Cell Therapy Coupling Angiogenesis and Osteogenesis for Bone Defect$313,144
R01 · FY2013 · AR · contact PI
Gene-Engineered and Targeted Stem Cell Therapy for Myeloma$274,339
R01 · FY2013 · CA · contact PI
Targeted Stem Cell Therapy Coupling Angiogenesis and Osteogenesis for Bone Defect$329,625
R01 · FY2012 · AR · contact PI
Gene-Engineered and Targeted Stem Cell Therapy for Myeloma$291,849
R01 · FY2012 · CA · contact PI
rAAV vaccine vector$291,849
R01 · FY2012 · CA · contact PI
Targeted Stem Cell Therapy Coupling Angiogenesis and Osteogenesis for Bone Defect$329,625
R01 · FY2011 · AR · contact PI
Gene-Engineered and Targeted Stem Cell Therapy for Myeloma$291,849
R01 · FY2011 · CA · contact PI
rAAV vaccine vector$291,849
R01 · FY2011 · CA · contact PI
UAB Core Center for Basic Skeletal Research (CCBSR)$565,122
P30 · FY2010 · AR · contact PI
rAAV vaccine vector$300,875
R01 · FY2010 · CA · contact PI
Gene-Engineered and Targeted Stem Cell Therapy for Myeloma$300,875
R01 · FY2010 · CA · contact PI
rAAV vaccine vector$300,875
R01 · FY2009 · CA · contact PI
Gene-Engineered and Targeted Stem Cell Therapy for Myeloma$291,538
R01 · FY2009 · CA · contact PI
AAV-Mediated Gene Therapy for Metabolic Bone Disease$267,698
R01 · FY2009 · AR · contact PI
rAAV vaccine vector$291,538
R01 · FY2008 · CA · contact PI
AAV-mediated gene therapy for metabolic bone disease$267,698
R01 · FY2008 · AR · contact PI
AAV-mediated gene therapy for metabolic bone disease$273,162
R01 · FY2007 · AR · contact PI
Gene Therapy for Prostate Cancer$244,726
R01 · FY2007 · CA · contact PI
AAV-mediated gene therapy for metabolic bone disease$281,320
R01 · FY2006 · AR · contact PI
Gene Therapy for Prostate Cancer$252,035
R01 · FY2006 · CA · contact PI
AAV-mediated gene therapy for metabolic bone disease$287,926
R01 · FY2005 · AR
Gene Therapy for Prostate Cancer$258,100
R01 · FY2005 · CA
Novel dendritic cell therapy for human cancers$238,569
R01 · FY2005 · CA
Gene Therapy for Prostate Cancer$258,100
R01 · FY2004 · CA
Novel dendritic cell therapy for human cancers$238,569
R01 · FY2004 · CA
Gene Therapy for Prostate Cancer$280,350
R01 · FY2003 · CA
Novel dendritic cell therapy for human cancers$238,569
R01 · FY2003 · CA
Novel dendritic cell therapy for human cancers$238,569
R01 · FY2002 · CA
Long term gene therapy for osteoporosis$0
P30 · FY2002 · AR